A carefully maintained longitudinal, observational study of patients treated with telaprevir and boceprevir within academic and real-world community practices can rapidly inform strategies:
- For better management of populations both represented and underrepresented in Ph III clinical trials
- To identify educational gaps relative to treatment guidelines and management of adverse events
- To develop a core for translational studies
- To implement a rapid clinical trials network for novel studies